Amphetamine induces hydroxyl radical formation in the striatum of rats

Life Sciences

Volumn 61, Issue 22, 1997, Pages 2219-2229

  Huang, Nai Kuei ^a   Fang Jung, Wan ^a   Tseng, Ching Jiunn ^b   Tung, Che Se ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Amphetamine; Dopamine; Hydroxyl radical; Striatum

Indexed keywords

2,3 DIHYDROXYBENZOIC ACID; AMPHETAMINE; DESIPRAMINE; DOPAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; RAT; STEREOTYPY;

EID: 0343580433     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00924-7     Document Type: Article

References (53)

1. A. PLETSCHER, W.P. BURKARD, H. BRUDERER and K.F. GEY, Life Sc. 11 828-833, (1963).
2. G.C. WAGNER, L.S. SEIDEN and C.R. SCHUSTER, Drug Alcohol Dep 4 435-438 (1979).
3. G.C. WAGNER, G.A. RICAURTE, L.S. SEIDEN, C. R. SCHUSTER, R.J MILLER and J. WESTLY, Brain Res. 181 151-160 (1980).
4. L.Y. KODA and J.W. GIBB, J. Pharmacol. Exp. Ther. 185 42-48 (1973).
5. G. ELLISON, M.S. EISO, H.S. HUBERMAN and F. DANIEL, Science 201 276-278, (1978).
6. D.M. KUHN, B. RUSKIN and W. LOVENGERG, J. Biol. Chem. 255 4137-4143 (1980).
7. L.S. SIEDEN and G. VOSMER, Pharmaco. Biochem. Behav. 21 29-31 (1984).
8. G.C. WAGNER, R.M. CARELLI and M.F. JARVIS, Res. Commun. Chem. Path. Pharmac. 47 221-228 (1985).
9. J.L. CADET, B. LADENHEIM, I. BAUM, E. CARLSON and C. EPSTEIN, Brain Res. 655 259-262 (1994a).
10. J.L. CADET, P. SHENG, S. ALI, R. ROTHMAN, E. CARLSON and C. EPSTEIN, J. Neurochem. 62 380-383 (1994b).
11. H. KAPPUS and H. SIES, Experientia 37 1233-1241 (1981).
12. M.J. DE VITO and G.C. WAGNER, Neuropharmacology 28 1145-1150 (1989).
13. A.J. HOTCHKISS and J.W. GIBB, J. Pharmacol. Exp. Ther. 214 257-262 (1980).
14. R.W. FULLER and S.K. HEMRICK-LUECKE, Neuropharmacology 21 433-438 (1982).
15. D.M. STONE, G.R. HANSON and J.W. GIBB, Soc. Neurosci. Abstr. 12 608 (1986).
16. D.M. STONE, M. JOHNSON, G.R. HANSON and J.W. GIBB, J. Pharmacol. Exp. Ther. 247 79-87 (1988).
17. R. KUCZENSKI and D.S. SEGAL, J. Neurosic. 9 2051-2065 (1989).
18. D.G. GRAHAM, Neurotoxicology 5 83-95 (1984).
19. G. COHEN, Ann. N. Y. Acad. Sci. 738 8-14 (1994).
20. T. OBATA and C.C. CHIUEH, J. Neurol, Transm. [G. Sec.], 89 139-145 (1993).
21. S.K. HEMRICK-LUECKE, M.G. HENDERSON and R.W. FULLER, Life Sci. 50 PL31-PL33 (1992)
22. J.F. BOWYER, P. CLAUSING, B. GOUGH, W. SLIKKER JR. and R.R. HOLSON, Brain Res. 699 62-70 (1995).
23. B. HAMMER, W.D. PARKER JR. and J.P. BENNET JR., NeuroReport 5 72-74 (1993).
24. M. LAFON-CAZAL, S. PIETRI, M. CULCASI and J. BOCKAERT, Nature 364 535-537 (1993).
25. J.T. COYLE and P. PUTTFARCKEN, Science 262 689-695 (1993).
26. C.W. OLANOW, Trends Neurosci. 16 439-441 (1993).
27. D.M. RADZIK, D.A ROSTON and P.T. KISSINGER, Anal. Biochem. 131 458-464 (1983).
28. B. HALLIWELL, H. KAUR and M. INGELMAN-SUNDBERG, Free Rad. Biol. Med. 10 439-411(1991).
29. S. CONSOLO, E. DOLFINI, S. GARATTINI and L. VALZELLI, J. Pharm. Pharmac. 19 253-256 (1967).
30. G. PAXINOS and C. WATSON, The Rat Brain in Stereotaxic Coordinates. Academic Press, Orlando (1986).
31. E.H. ELLINWOOD JR. and R.L. BALSTER, Eur. J. Pharmacol. 28 35-41 (1974).
32. L. STEIN, Fedn. Pro. Fedn. Am. Socs. Exp. Med. 23 836-856 (1964).
33. J.J. FREEMAN and F. SULSTER, J. Pharmacol. Exp. Ther. 183 307-315 (1972).
34. R.W. FULLER and S.K. HEMRICK-LUECKE, Science 209 395-397 (1980).
35. E. NWAZE and G. JONSSON, Neurosci. Lett. 26 163-168 (1981).
36. L.R. STERANKA and E. SANDERS-BUSH, Eur. J. Pharmacol. 65 439-443 (1980).
37. A.K. CHO, B.J. HODSHON, B. LINDEKE and G. MIWA, J. Pharm. Sci. 62 1491-1494 (1973).
38. T.B. VREE, Pharmacokinetics and Metabolism of Amphetamine, Ph.D. Thesis, Catholic University Nijmegen, The Netherlands (1973).
39. L. LEMBERGER, E. SERNATINGER and R. KUNTZMAN, Biochem. Pharmacol. 19 3021-3028 (1970).
40. T. KONDO, T. ITO and Y. SUGITA, Ann. N. Y. Acad. Sci. 738 222-229 (1994).
41. L.S. SIEDEN and G.A. RICAURTE, Psychopharmacology: Third Generation of Progress, H.Y. Meltzer (Eds) 359-366, Raven Press, New York (1987).
42. D.G. GRAHAM, S.M. TIFFANY, W.R. JR. BELL and W.F. GUTKNECHT, Mol. Pharmacol. 14 644-653 (1978).
43. T.J.MONNKS, R.P. HANZLIK, G.M. COHEN, D. ROSS and D.G.GRAHAM, Toxicol. Appl. Pharmacol. 112 2-16 (1992).
44. G. COHEN and R.E. HEIKKILA, J. Biol. Chem. 249 2447-2452 (1974).
45. H.S. MAKER, C. WEISS and T.S. BRANNAN, Neuropharmacology 25 25-32 (1986).
46. G. PILEBLAD, A. SLIVKA, D. BRATVOLD and G. COHEN, Arch. Biochem. Biophys. 263 447-452 (1988).
47. B. HALLOREN and P. SOURANDER, J. Neurochem. 3 41-51 (1958).
48. G.D. ELLISON, Biological Basis of Substance Abuse, S.G. Korenman and J.D. Barchas (Eds) 355-377, Oxford University Press, New York (1993).
49. J.L. CADET, S. ALI and C. EPSTEIN, Ann. N. Y. Acad. Sci. 738 388-391 (1994).
50. J.F. NASH and B.K YAMAMOTO, Brain Res. 627 1-8 (1993).
51. D.B. CALNE, F.H. HOCHBGER, B.J. SNOW and T. NYGAARD, Ann. N.Y. Acad. Sci. 648 1-5 (1992).
52. D. BEN-SHACHAR, R. ZUK and Y. GLINKA, J. Neurochem. 64 718-723 (1995).
53. C.B. THOMPSON, Science 267 1456-1462 (1995).